AMPIO PHARMACEUTICALS INC (AMPE) Fundamental Analysis & Valuation

NYSEARCA:AMPE • US03209T3077

Current stock price

0.62 USD
-0.09 (-12.91%)
Last:

This AMPE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AMPE Profitability Analysis

1.1 Basic Checks

  • AMPE had negative earnings in the past year.
  • AMPE had a negative operating cash flow in the past year.
  • In the past 5 years AMPE always reported negative net income.
  • In the past 5 years AMPE always reported negative operating cash flow.
AMPE Yearly Net Income VS EBIT VS OCF VS FCFAMPE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M

1.2 Ratios

  • AMPE has a Return On Assets of -150.51%. This is amonst the worse of the industry: AMPE underperforms 88.27% of its industry peers.
  • The Return On Equity of AMPE (-256.93%) is worse than 77.04% of its industry peers.
Industry RankSector Rank
ROA -150.51%
ROE -256.93%
ROIC N/A
ROA(3y)-104.9%
ROA(5y)-96.3%
ROE(3y)-152.7%
ROE(5y)-152.1%
ROIC(3y)N/A
ROIC(5y)N/A
AMPE Yearly ROA, ROE, ROICAMPE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

  • AMPE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMPE Yearly Profit, Operating, Gross MarginsAMPE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AMPE Health Analysis

2.1 Basic Checks

  • AMPE has more shares outstanding than it did 1 year ago.
  • AMPE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMPE Yearly Shares OutstandingAMPE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
AMPE Yearly Total Debt VS Total AssetsAMPE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

  • AMPE has an Altman-Z score of -63.84. This is a bad value and indicates that AMPE is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -63.84, AMPE is doing worse than 92.35% of the companies in the same industry.
  • There is no outstanding debt for AMPE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -63.84
ROIC/WACCN/A
WACCN/A
AMPE Yearly LT Debt VS Equity VS FCFAMPE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

  • AMPE has a Current Ratio of 2.41. This indicates that AMPE is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMPE (2.41) is comparable to the rest of the industry.
  • AMPE has a Quick Ratio of 2.32. This indicates that AMPE is financially healthy and has no problem in meeting its short term obligations.
  • AMPE has a Quick ratio (2.32) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.32
AMPE Yearly Current Assets VS Current LiabilitesAMPE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. AMPE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 48.86% over the past year.
EPS 1Y (TTM)48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMPE Yearly EPS VS EstimatesAMPE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. AMPE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AMPE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMPE Price Earnings VS Forward Price EarningsAMPE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMPE Per share dataAMPE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMPE Dividend Analysis

5.1 Amount

  • AMPE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPE Fundamentals: All Metrics, Ratios and Statistics

AMPIO PHARMACEUTICALS INC

NYSEARCA:AMPE (4/12/2024, 8:04:00 PM)

0.62

-0.09 (-12.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25
Earnings (Next)05-06
Inst Owners0.01%
Inst Owner Change-0.89%
Ins Owners522.18%
Ins Owner Change0%
Market Cap514.60K
Revenue(TTM)N/A
Net Income(TTM)-8.63M
Analysts43.33
Price Target2.04 (229.03%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB 0.15
EV/EBITDA N/A
EPS(TTM)-11.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-10.32
FCFYN/A
OCF(TTM)-10.32
OCFYN/A
SpS0
BVpS4.05
TBVpS4.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -150.51%
ROE -256.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.9%
ROA(5y)-96.3%
ROE(3y)-152.7%
ROE(5y)-152.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.32
Altman-Z -63.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.91%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.47%
OCF growth 3YN/A
OCF growth 5YN/A

AMPIO PHARMACEUTICALS INC / AMPE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AMPIO PHARMACEUTICALS INC (AMPE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to AMPE.


What is the valuation status for AMPE stock?

ChartMill assigns a valuation rating of 0 / 10 to AMPIO PHARMACEUTICALS INC (AMPE). This can be considered as Overvalued.


Can you provide the profitability details for AMPIO PHARMACEUTICALS INC?

AMPIO PHARMACEUTICALS INC (AMPE) has a profitability rating of 0 / 10.